TY - JOUR AU - Dormán, György AU - Buchholcz, Balázs AU - Puskás, István AU - Szabó, Pál Tamás AU - Varga, Erzsébet AU - Szente, Lajos AU - Keserű, György Miklós AU - Darvas, Ferenc TI - Repetitive stability study of remdesivir/cyclodextrin complex on the international space station JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 15 PY - 2025 IS - 1 SN - 2045-2322 DO - 10.1038/s41598-024-81428-5 UR - https://m2.mtmt.hu/api/publication/35739403 ID - 35739403 N1 - Funding Agency and Grant Number: National Drug Research and Development Laboratory [PharmaLab RRF-2.3.1-21-2022-00015]; National Research, Development and Innovation Office [TKP2021-EGA-31] Funding text: We are grateful to Paul G. Mezey (Yukawa Institute for Theoretical Physics, Kyoto University) for valuable discussions on the theoretical aspects of microgravity. Pal Szabo and Gyoergy M Keser & udblac; were supported by the National Drug Research and Development Laboratory (PharmaLab RRF-2.3.1-21-2022-00015) and (TKP2021-EGA-31) sponsored by the National Research, Development and Innovation Office. AB - Stability assessment of drugs in space is particularly important for future missions. In space there are multiple factors, such as the variability of the conditions (radiation, microgravity, vacuum etc.) that could affect the reliability and reproducibility of the data. Therefore, we investigated the stability of an anti-Covid drug formulation, Remdesivir (RDV) sulfobutylether-beta-cyclodextrin (SBECD) complex, in two separate flight experiments on the International Space Station (ISS). While HPLC/MS studies revealed no degradation of the cyclodextrin excipient in any of the samples investigated in both missions, RDV purity analysis of the RDV/SBECD complex after the first mission revealed different stabilities and altered degradation in space and on Earth. This latter interesting finding was not supported by the second mission, where no differences in the drug stabilities were identified. This anomaly highlighted the importance of standardization together with increased control of the variable parameters during the entire space missions and the terrestrial control experiments. LA - English DB - MTMT ER - TY - JOUR AU - Anderson, Amelia AU - O'Connor, Matthew S. AU - Pipkin, James AU - Malanga, Milo AU - Sohajda, Tamás AU - Loftsson, Thorsteinn AU - Szente, Lajos AU - García-Fandiño, Rebeca AU - Piñeiro, Ángel TI - A comprehensive nomenclature system for cyclodextrins JF - CARBOHYDRATE POLYMERS J2 - CARBOHYD POLYM VL - 360 PY - 2025 SP - 123600 SN - 0144-8617 DO - 10.1016/j.carbpol.2025.123600 UR - https://m2.mtmt.hu/api/publication/36097455 ID - 36097455 LA - English DB - MTMT ER - TY - JOUR AU - Corning, Chloe AU - Dolatmoradi, Marjan AU - Tran, Tina H. AU - Stacey, Gary AU - Szente, Lajos AU - Samarah, Laith Z. AU - Vertes, Akos TI - Degree of polymerization and spatial distributions of acyclic and cyclic oligohexoses in soybean root nodules uncovered by MALDI and nanophotonic laser desorption ionization mass spectrometry JF - MATERIALS TODAY BIO J2 - MATER TODAY BIO VL - 32 PY - 2025 SP - 101776 SN - 2590-0064 DO - 10.1016/j.mtbio.2025.101776 UR - https://m2.mtmt.hu/api/publication/36113345 ID - 36113345 LA - English DB - MTMT ER - TY - JOUR AU - Szente, Lajos AU - Tuza, Kata AU - Herr, Dominika Mária AU - Varga, Erzsébet AU - Szőcs, Levente AU - Fenyvesi, Éva AU - Puskás, István TI - Rapid test for identification of heptakis (2,6-di-O-methyl) β-cyclodextrin in isomeric mixtures JF - JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY J2 - J INCL PHENOM MACRO CHEM VL - 105 PY - 2025 SP - 513 EP - 523 PG - 11 SN - 1388-3127 DO - 10.1007/s10847-025-01304-1 UR - https://m2.mtmt.hu/api/publication/36118511 ID - 36118511 N1 - Funding Agency and Grant Number: National Research, Development and Innovation Office; [2020 - 1.1.2-PIACI-KFI-2020-00092]; [2024 - 1.2.7-EUROSTARS-2024-00002] Funding text: The work was performed in the frame of project No. 2020 - 1.1.2-PIACI-KFI-2020-00092 and 2024 - 1.2.7-EUROSTARS-2024-00002 supported by the National Research, Development and Innovation Office. LA - English DB - MTMT ER - TY - JOUR AU - Benkő, Beáta Mária AU - Szabó, B.-I. AU - Kádár, Szabina AU - Szabó, Edina AU - Tóth, Gergő AU - Szente, Lajos AU - Tonka-Nagy, P. AU - Zelkó, Romána AU - Sebe, István TI - Development of Low-Dose Disulfiram Rectal Suppository Intended for Application in Post-Treatment Lyme Disease Syndrome JF - PHARMACEUTICS J2 - PHARMACEUTICS VL - 17 PY - 2025 IS - 7 PG - 25 SN - 1999-4923 DO - 10.3390/pharmaceutics17070849 UR - https://m2.mtmt.hu/api/publication/36216612 ID - 36216612 N1 - B-M.B.: Supported by the EKÖP-2024-128 New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund. G.T.: This work was funded by the National Research, Development, and Innovation Office, Hungary (grant: NKFIH FK 146930). S.K.: This work was supported by EKÖP-24-4-I-BME-127 University Research Fellowship Programme of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund. G.T.: This work was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences. AB - Background/Objectives: Early diagnosis and oral or, in severe cases, intravenous antibiotics are usually effective for Lyme disease, but some patients have persistent symptoms unresponsive to standards of care, requiring alternative therapies. Disulfiram (DIS), a drug for alcoholism, is under investigation as a potential adjunctive treatment, but its low bioavailability, rapid metabolism, and safety concerns urge the development of improved formulations for clinical translation. Methods: Screening dissolution and permeation studies were investigated for vehicle and excipient selection, following the pharmacopeia perspectives to develop and optimize the low-dose DIS rectal suppository intended for application in post-treatment Lyme disease syndrome (PTLDS). Further characterizations were carried out by differential scanning calorimetry, X-ray diffraction, and infrared spectroscopy. Results: Cyclodextrin (CD) encapsulation was investigated to improve the aqueous solubility of the hydrophobic drug. The dissolution of DIS from fatty base suppository was very slow; it was remarkably improved by the molecular encapsulation of the drug with CDs. The dissolution of DIS from a water-soluble base was more favorable, but incomplete. In the polyethylene glycol (PEG) based suppositories, the addition of CDs already in a physical mixture ensured the dissolution of the drug. The presented drug delivery system relates to a novel preparation for rectal administration comprising a low-dose disulfiram with improved solubility and permeability by the PEG and hydroxypropyl-β-cyclodextrin (HPBCD) synergistic matrix. Conclusions: The rectal dosage form containing the drug and CD in the physical mixture is advantageous, avoiding the hepatic first-pass effect, minimizing dose-limiting toxicity, simplifying production, and fasting the availability of the repositioned drug. LA - English DB - MTMT ER - TY - JOUR AU - Márton, Rita AU - Hermann, Hanna AU - Kiss, Virág Tünde AU - Fenyvesi, Éva AU - Szente, Lajos AU - Molnár, Mónika TI - Cyclodextrins in Action: Modulating Candida albicans Biofilm Formation and Morphology JF - BIOTECHNOLOGY REPORTS J2 - BIOTECHNOLOGY REP VL - 47 PY - 2025 PG - 10 SN - 2215-017X DO - 10.1016/j.btre.2025.e00912 UR - https://m2.mtmt.hu/api/publication/36286982 ID - 36286982 N1 - This research was funded by the Richter Gedeon Excellence Ph.D. Scholarship of Richter Gedeon Talentum Foundation (H-1103 Budapest, Gyömrői str. 19-21, Hungary) and the Ministry of Culture and Innovation of Hungary from the Hungarian National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme. AB - The primary objective of this research was to explore the bioactive potential of cyclodextrins in attenuating biofilm formation in C. albicans. The concentration-dependent effects of both native cyclodextrins and specific derivatives were studied at concentrations ranging from 0.1 to 12.5 mM, to determine the mechanisms by which the extent of biofilm formation can be reduced. Besides, the efficiency of various combinations of cyclodextrins and farnesol, as an antifungal substance, were examined. The present study revealed both stimulatory and inhibitory effects of cyclodextrins on biofilm formation, depending on the structure and concentration. The bioactive potential of randomly methylated α- and γ-CD showed significant antifungal properties, as evidenced by a reduction in the biofilm formation. In addition, randomly methylated cyclodextrins were found to significantly enhance the antifungal activity of farnesol against C. albicans. Consequently, their synergistic effect may provide an excellent opportunity to produce a lower dose but more effective anticandidal formulation. © 2025 Elsevier B.V., All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Szente, Lajos AU - Balogh, György Tibor TI - Főszerkesztői levél JF - MAGYAR KÉMIAI FOLYÓIRAT - KÉMIAI KÖZLEMÉNYEK (1997-) J2 - MAGY KÉM FOLY KÉM KÖZL VL - 131 PY - 2025 IS - 1 SP - 3 SN - 1418-9933 UR - https://m2.mtmt.hu/api/publication/36292080 ID - 36292080 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Szente, Lajos AU - Balogh, György Tibor TI - Gyászhír: Görög Sándor JF - MAGYAR KÉMIAI FOLYÓIRAT - KÉMIAI KÖZLEMÉNYEK (1997-) J2 - MAGY KÉM FOLY KÉM KÖZL VL - 131 PY - 2025 IS - 1 SP - 4 SN - 1418-9933 UR - https://m2.mtmt.hu/api/publication/36292084 ID - 36292084 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Szente, Lajos AU - Fenyvesi, Éva TI - Special Issue “A Commemorative Issue in Honor of József Szejtli: Advances in Cyclodextrin Chemistry and Its Applications” JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 26 PY - 2025 IS - 18 SP - 9246 SN - 1661-6596 DO - 10.3390/ijms26189246 UR - https://m2.mtmt.hu/api/publication/36344249 ID - 36344249 AB - This Special Issue is dedicated to the memory of the late Dr [...] LA - English DB - MTMT ER - TY - JOUR AU - Puskás, István AU - Szente, Lajos AU - Ürögi, Zsolt AU - Szakály, Péter Soma AU - Varga, Erzsébet AU - Fenyvesi, Éva TI - Synthesis and use of heptakis(2,6-di-O-methyl)-beta-cyclodextrin related to therapeutic applications: Patent and literature review JF - INTERNATIONAL JOURNAL OF PHARMACEUTICS J2 - INT J PHARM VL - 686 PY - 2025 PG - 12 SN - 0378-5173 DO - 10.1016/j.ijpharm.2025.126305 UR - https://m2.mtmt.hu/api/publication/36411197 ID - 36411197 N1 - The work was performed in the frame of project No. 2020-1.1.2-PIACI-KFI-2020-00092 and 2024-1.2.7-EUROSTARS-2024-00002 supported by the National Research, Development and Innovation Office. Project KT-2023-900-I1-00000975/0000003 has been implemented with the support provided by the Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund, financed under the KDP-2023 funding scheme. AB - The heptakis(2,6-di-O-methyl)-beta-cyclodextrin (DIMEB), a methylated beta-cyclodextrin isomer has gained special interest due to its outstanding properties including high solubility and excellent solubilizing effect. It was found to enhance the pertussis toxin production in 1980s and has been used as an auxiliary material in manufacturing acellular pertussis vaccine since then. This vaccine applied world-wide against whooping cough has maintained the demand for DIMEB. In the meantime, further applications were discovered in other biotechnologies, drug delivery and tissue imaging. The high potential in the use as a therapeutic agent was also studied by several research groups. The increasing amount of knowledge concerning DIMEB calls for a systematic review. In this work we give the background based on the scientific literature and patents on the synthesis, effect and mechanism of action of this special cyclodextrin derivative. In relation to its applications, also, suitable analytical methods are enumerated to distinguish various methylated species of beta-cyclodextrins. Industrially produced DIMEB is a mixture of methylated cyclodextrin isomers containing at least 40 % of the specific single isomer heptakis(2,6-di-O-methyl)-beta-cyclodextrin. It was proved that this special methylation pattern has several advantages over the other methylated beta-cyclodextrin isomers including enhanced solubilizing and stabilizing effect, increased catalytic activity in various biotechnologies and special cellular effects with a potential in the therapy of various diseases. LA - English DB - MTMT ER -